Compare GBTG & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GBTG | CRSP |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United Kingdom | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.9B |
| IPO Year | 2020 | 2016 |
| Metric | GBTG | CRSP |
|---|---|---|
| Price | $9.34 | $54.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 17 |
| Target Price | $8.92 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 5.5M | 1.6M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 173.33 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $2,718,000,000.00 | $289,590,000.00 |
| Revenue This Year | $21.78 | $807.72 |
| Revenue Next Year | $4.29 | $172.52 |
| P/E Ratio | $93.40 | ★ N/A |
| Revenue Growth | 12.17 | ★ 9169.85 |
| 52 Week Low | $4.96 | $39.81 |
| 52 Week High | $9.54 | $78.48 |
| Indicator | GBTG | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 75.48 | 56.30 |
| Support Level | $9.34 | $50.33 |
| Resistance Level | $9.46 | $55.73 |
| Average True Range (ATR) | 0.06 | 2.27 |
| MACD | -0.12 | 0.61 |
| Stochastic Oscillator | 13.16 | 74.22 |
Global Business Travel Group Inc operates as a business-to-business travel platform. It is engaged in providing software and services to manage travel, expenses, and meetings and events for companies of all sizes. The company is engaged in building the marketplace in B2B travel to deliver unrivaled choice, value, and experiences. It also provides business travel solutions, simplified travel management, and business consulting services. Further, The company generates revenue in two ways that involves fees and other revenues relating to processing and servicing travel transactions received from clients and travel suppliers and revenues for the provision of products and professional services not directly related to transactions received from clients, travel suppliers and Network Partners.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.